Recently, graphene, another allotrope of carbon, has also shown promise in various biomedical applications. In this article, we will highlight recent research on these two categories of closely related carbon nanomaterials for applications in drug delivery and cancer therapy, and discuss the opportunities and challenges in this rapidly growing field.
in biomedicine 9, [14] [15] [16] [17] . Herein, we focus on carbon nanotubes and graphene for drug delivery and cancer treatment. In vitro cell uptake and intracellular molecular transport with CNTs are initially discussed.
Encouraging in vitro results prompted further research of CNT-based drug delivery for in vivo cancer treatment. Recent progress on using graphene in the field of drug delivery is also reviewed. In addition to the delivery of therapeutic molecules, carbon nanotubes and graphene demonstrate strong optical absorption in the near-infrared (NIR) region, making them promising materials for use in the photothermal ablation of tumors. Despite the encouraging pre-clinical results shown by various groups, several obstacles must be overcome before these carbon nanomaterials can be put to clinical use. To conclude, the future challenges and prospects of using CNTs and graphene in nanomedicine, as well as the comparison between them, will be addressed.
Interactions of carbon nanotubes with cells
Motivated by the unique 1D structure of CNTs, a number of groups explored the possible entry of nanotubes into cells as early as 2004 [18] [19] [20] . Numerous reports have shown that functionalized, watersoluble CNTs are able to enter cells, although the exact uptake mechanism for CNTs may depend on the size and surface chemistry.
The majority of studies over the past several years have uncovered that CNTs functionalized by oxidization, wrapped by DNA, and coated by surfactants or amphiphilic polymers are able to be engulfed by cells via the energy-dependent endocytosis pathway 8, [20] [21] [22] [23] [24] [25] [26] . This entryway is similar to many other nanomaterials used in biomedicine. However, it has also been reported that CNTs functionalized by the 1,3-dipolar cycloaddition, or Prato reaction, entered cells by passive diffusion owing to the needle-like structure of nanotubes 19, 27, 28 . Besides surface chemistry, the size of CNTs plays an important role in their interaction with cells. A recent study uncovered that the endocytosis pathway for 100 -200 nm SWNTs was mainly through clathrin-coated pits, but shorter SWNTs (50 -100 nm) were internalized through clathrincoated vesicles as well as the caveolae pathway 29 . Work by Yan and co-workers proposed that individual MWNTs could enter cells through direct penetration while MWNT bundles are taken up by cells through endocytosis 30 .
After endocytosis CNTs were mainly located inside cell endosomes and lysosomes. Whether CNTs can escape from these membranebound compartments inside cells may also depend on the sizes and surface coating. While SWNTs functionalized by DNA or PEG are mostly retained inside endosomes and lysosomes 22, 23, [31] [32] [33] , it has been found that individualized MWNTs were able to travel through various cellular barriers and even entered the nucleus 28, 30 . In a recent work, Zhou et al. found that by conjugating different molecules to PEGfunctionalized SWNTs, nanotubes were able to localize in specific subcellular organelles such as mitochondria 34 .
The possibility and mechanism of CNTs escaping from cells after cellular uptake is another important question. By using the intrinsic photoluminescence of SWNTs to track nanotubes inside cells, Jin et al. discovered that DNA-coated SWNTs could undergo exocytosis after entering cells via endocytosis 23 . Interestingly, the rate of exocytosis was again closely related to the length of the nanotubes, showing slower cellular expulsion for longer nanotubes 35 . Obviously, the surface chemistry and sizes of CNTs play critical roles in regulating the interactions of CNTs with cells. It is thus crucial to correctly select and control the surface coatings, diameters, and lengths of CNTs to achieve specific aims in CNT-based biomedical applications.
Carbon nanotubes in animals
In the past several years, there have been numerous papers that studied the behavior of carbon nanotubes in animals. The in vivo pharmacokinetics, biodistribution, long-term fate, and toxicology of CNTs, which are closely associated with their surface chemistries, sizes, doses, and administration routes, are rather complicated issues, and thus not the focus of this current review article [36] [37] [38] [39] [40] [41] . Although there are certain debates on the clearance mechanism of nanotubes, the majority of studies have suggested that functionalized CNTs, when intravenously injected into animals (e.g., mice, rats), tended to accumulate in the reticuloendothelial system including the liver and spleen, and were gradually excreted, likely via both fecal and renal excretion 39, [42] [43] [44] [45] [46] [47] . Recent work by our group investigated the behavior of SWNTs in vivo at early time points after intravenous injection. The SWNTs were tracked using their intrinsic near-infrared photoluminescence (NIR PL) for several minutes after injection.
Utilizing principle component analysis (PCA), our group was able to identify the time course of SWNTs through individual organs, including the liver, lungs, spleen, and kidneys 48 .
Toxicity is a major concern in using CNTs for biomedical applications. Orally-fed CNTs suspended by surfactants appeared to be safe even at an ultra-high dose of up to 1000 mg/kg 44 . Intratrachealadministration of unfunctionalized CNTs aggregated in the lungs and led to pulmonary toxicity and inflammation. This aggregation, however, was not seen for well-dispersed, individualized SWNTs 43,49-51 .
Intraperitoneally injected, large MWNTs, and SWNT bundles induced inflammation and granuloma formation, which again was not found for small MWNTs and individualized SWNTs 44, 52 . Compared with nonfunctionalized, raw CNTs, well-functionalized CNTs with biocompatible coatings (e.g., by PEGylation) exhibited remarkably reduced in vivo toxicity after being intravenously injected into animals 38, 39, 53, 54 . How CNTs affected the fertility 55 and induced immune responses 56,57 after administration to animals has only been partially studied and needs future attention.
Delivery of small drug molecules by carbon nanotubes
Drug delivery is one of the most extensively explored applications of CNTs in biomedicine. In recent years, different strategies have been developed by various groups to load small molecules such as chemotherapeutic cancer drugs on CNTs via either covalent conjugation or non-covalent adsorption (Fig. 1) . Theoretical modeling has also been used to guide the design of CNT-based drug carriers [58] [59] [60] [61] .
Covalently conjugated drug molecules are linked to the functional groups on the CNT surface or to the polymer coating of CNTs, usually via cleavable bonds. Anti-cancer or anti-fungal drugs were linked by 1,3-dipolar cycloaddition to functionalized CNTs via amide bonds for drug delivery 62, 63 . The Lippard group and our group used non-covalently PEGylated SWNTs as a longboat delivery system for intracellular transportation of a platinum(IV) complex, which was then reduced to cytotoxic platinum(II) after endocytosis for cancer cell destruction 64, 65 . Other chemotherapeutics such as paclitaxel and cisplatin have been covalently conjugated to CNTs for in vitro and in vivo drug delivery 45, 66, 67 .
Besides covalent linkage, aromatic molecules with a flat structure can be adsorbed on the surface of CNTs via non-covalent π-π stacking. In 2007, our group discovered that doxorubicin, a commonly used cancer chemotherapy drug, could be stacked on the surface of PEGylated SWNTs with a remarkably high loading capacity of up to 4 grams of drug per 1 gram of nanotubes (Fig. 2a) , owing to the ultrahigh surface area of SWNTs 68 . The pH-dependent drug binding and releasing behaviors are favorable for drug release in endosomes and lysosomes, as well as in tumor micro-environments with acidic pH. This π-π stacking based drug loading strategy was applied to MWNTs and nano-graphene in other studies 15, 16, 69, 70 . 
Delivery of biomacromolecules by carbon nanotubes
Differing from small drug molecules which are usually able to diffuse 
Physical therapies of cancer introduced by carbon nanotubes
The SWNTs were also used for in vivo photothermal treatment of tumors by Moon et al. 90 In their work, carcinoma xenografts growing on nude mice were ablated after being directly injected with PEGylated SWNTs and subsequently exposed to an 808 nm laser. It was found that SWNTs injected into tumors accumulated in the nearby muscle and skin after tumors were destroyed, and then slowly translocated into the liver and spleen, from which nanotubes were gradually excreted. The major limitation of any photo-therapy is the absorption and scattering of light by biological tissues, even when NIR light is used.
Gannon et al. discovered that SWNTs were able to generate heat in a 13.6 MHz radiofrequency (RF) field, which had excellent tissue penetration ability 94 . The RF-induced SWNT heating was then used to ablate cancer cells in vitro and xenograft tumors growing on rabbits in vivo. RF ablation therapy with SWNTs could overcome the limitation of photo-therapies and may be used to treat large or internal tumors.
Fig. 3 NIR fluorescence imaging guided photothermal therapy with SWNTs. (a) A digital photo and (b) a NIR photoluminescence image of a BALB/c mouse with two 4T1 tumors (indicated by arrows) taken after intravenous injection of PEGylated SWNTs. IR thermal images of tumor-bearing mice (c) with and (d) without injection of SWNTs under 808 nm laser irradiation for 4.5 minutes (0.6 W/cm 2 ). (e,f) The corresponding photos of mice before the NIR irradiation. (g) Tumor growth curves and (h) animal survival curves of 4T1 tumor bearing mice after SWNT-based photothermal therapy. 4T1 tumor bearing mice with or without SWNT injection (3.6 mg/kg) were exposed to the 808 nm laser at 0.6 W/cm 2 power for 5 min. All mice from the treatment group were surviving and tumor-free at the end of two months. © 2010. Reproduced with kind permission from Springer Science+Business Media and Tsinghua Press 91 .
(a)
However, there has not been any follow-up study since the first report in 2007. More efforts are required to further explore the potential of this interesting cancer treatment technique.
Graphene for drug delivery and cancer treatment
Graphene is an sp 2 Numerous graphene-based biosensing devices and techniques based on various mechanisms have been developed in the past few years 9,14,95 .
Sharing a similar chemical structure with CNTs, graphene can also be used as a drug delivery carrier 15, 16, [96] [97] [98] . Recently, in vivo cancer treatment with graphene has been realized in animal experiments 17 .
Motivated by the success of CNT-based drug delivery, we researched the possibility of using graphene sheets as drug carriers for potential cancer treatment. In our two related studies in 2008 15, 16 , graphene oxide (GO) was functionalized with amine-terminated branched PEG, yielding PEGylated nano-graphene oxide (N GO-PEG) with ultra-small sizes (10 -50 nm) and high stability in physiological solutions (Figs. 4a-c) . Similar to the drug loading on CNTs, the graphene surface with delocalized π electrons can be utilized for effective loading of aromatic anticancer drugs such as doxorubicin and water-insoluble SN 38 via π-π stacking (Fig. 4a ). The extremely large surface area of graphene, with every atom exposed on its surface, allowed for ultra-high drug loading efficiency on NGO-PEG. The terminals of PEG chains were available for the conjugation of targeting ligands such as antibodies, which facilitated targeted drug delivery to specific types of cancer cell (Fig. 4f) . Moreover, we discovered that NGO exhibited NIR photoluminescence. Although relatively weak, nano-graphene oxide NIR photoluminescence was utilized for selective imaging of cancer cells in vitro (Figs. 4d,e) . Similar to CNTs, NGO showed strong NIR optical absorption, which was greatly enhanced following chemical reduction. The reduced NGO was targeted at cancer cells for in vitro NIR photothermal therapy while still maintaining biocompatibility 70 . Recently, additional studies in drug loading and delivery via graphene have been reported by several groups 96, 99, 100 .
Besides the delivery of small drug molecules, the latest reports suggested that functionalized graphene sheets were capable of gene transfection. In our recent work 98 , negatively charged GO was non-covalently bound with cationic PEI polymers, forming GO-PEI complexes, which were stable in physiological solutions and exhibited significantly reduced cellular toxicity compared with bare PEI polymers.
The positively charged GO-PEI complexes were able to further bind Although graphene has poorer optical properties, the 2D shape and ultra-small sizes of nano-graphene (down to 10 nm and below) may offer interesting behaviors in biological systems (e.g., efficient tumor passive targeting) 17 . Therefore, it is still too early to determine which one among these two types of closely related sp 2 carbon nanomaterials has the greater potential for biomedical applications.
The major challenge and current limitation in this area, however, is still the potential long-term toxicity concern of graphitic nanomaterials.
Although many reports have suggested that well-functionalized CNTs and nano-graphene appear to be safe to the treated animals at certain 
